TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising early trial: patisiran may ease nerve damage in rare amyloidosis
Disease control CompletedThis early-phase study looked at how well the drug patisiran works for people with a rare disease called wild-type ATTR amyloidosis that causes nerve damage. Ten adults received the treatment, and researchers tracked changes in nerve function, symptoms like dizziness and digestio…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
New shot every 3 months shows promise for rare nerve disease
Disease control CompletedThis study tested a new drug called vutrisiran in 164 adults with a rare inherited disease that damages nerves and organs. Participants received either vutrisiran every 3 months or a standard treatment every 3 weeks. The goal was to see if vutrisiran could slow nerve damage and i…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Protein clues could predict amyloidosis onset
Knowledge-focused CompletedThis study followed 37 people with a genetic risk for hereditary ATTR amyloidosis over five years. Researchers measured a specific misfolded protein in the blood to see if it could signal when the disease starts or worsens. No treatments were tested; the goal was simply to learn …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 05:53 UTC
-
Can MRI and MUNIX catch nerve disease before symptoms start?
Knowledge-focused CompletedThis study looked at 60 people with a genetic mutation that can cause a severe nerve disease called familial amyloid neuropathy. The goal was to see if two tests—MRI scans and a special electrical test called MUNIX—can detect the very first signs of nerve damage, before symptoms …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated May 26, 2026 05:46 UTC